Loading organizations...
Key people at Maroon Invest Global.
Maroon Invest Global functions as a dedicated venture-growth fund, strategically deploying anchor capital into innovative early-stage ventures. The firm primarily invests in companies ranging from Pre-Seed to Series A+, with a clear focus on critical sectors such as Health, BioTech, Climate, and other impact-driven industries. It aims to provide foundational financial support to accelerate growth and innovation within these specialized domains.
Founded in 2022, Maroon Invest Global was established to address significant funding requirements within its target sectors. While detailed founder biographies are not publicly available, key team members, including Lisa Lambie, Randy Berholtz, and Timmeko Moore Love, are central to the fund's operational strategy. The organization draws upon its team's collective experience in both institutional investing and successful venture development to guide its portfolio.
The fund's client base consists of early-stage companies seeking strategic capital to scale their operations and refine their core offerings. Maroon Invest Global’s long-term vision centers on fostering the development of enterprises that generate substantial positive societal and environmental impact. It endeavors to be a crucial early partner for entrepreneurs creating solutions in its core areas, facilitating their path toward market prominence and lasting influence.
Maroon Invest Global is an impact investment platform and emerging fund manager based in San Francisco (with presences in New York and global operations), functioning as both a fund-of-funds investor in venture capital funds and a direct investor-operator in early-stage ventures (Pre-Seed to Series A/B).[1][2][5] Its mission centers on advancing Healthy Aging & Longevity by addressing funding gaps in preventative health, precision medicine, and climate-health intersections, such as women's health/FemTech, diverse demographics, built environment innovations, and blue economy solutions, while delivering measurable impact and attractive returns for diverse-led teams.[1][2] The investment philosophy emphasizes deep diligence, risk mitigation through credit/portfolio expertise, and GP accountability via financial KPIs, targeting underrepresented areas like preventative/public health (only 4% of healthcare investment) and climate-health (only 2% of climate finance).[2][3]
Key sectors include biotechnology, healthcare, medtech, renewables, climate impact on health, and women's health, with geographic focus on UK, US, Canada, Asia, Africa, and the Caribbean.[1][2] Maroon significantly impacts the startup ecosystem by providing anchor capital, scaling support, and ecosystem building for innovative ventures tackling chronic population health conditions (affecting 50% of the US population and driving 80% of costs) and environmental health risks.[2]
Maroon Invest Global emerged around 2022 as a platform launching Maroon Venture Fund I LP, a US-based venture-growth fund investing in Seed to Series A+ ventures.[1][2][5] Its founding team comprises seasoned professionals with roots in institutional investing and venture building; key figures include Timmeko Moore Love, General Partner with 17 years as GP/LP managing $600M AUM, 6.8x MOIC, 16 venture exits, and roles at Mayo Clinic Ventures, Entergy Ventures, and Greentown Labs (MBA Columbia, MSc Cornell).[3] Other expertise spans family offices, precision medicine ventures, and LP commitments with firms like JP Morgan and Wharton Impact Investing Partners.[3]
The focus evolved from broad impact investing to a sharpened thesis on healthy aging and longevity, driven by team track records in fund exits, IPOs, and scaling health/climate ventures amid gaps like the US's low life expectancy ranking despite high pharma profits.[2][3] Early momentum includes building a global team, with active recruitment for General Partners in EMEA (Middle East) and Asia to expand coverage.[4]
Maroon rides the longevity economy wave—projected to reach trillions globally—by targeting preventative health and climate-health nexus, where market forces like rising chronic diseases (80% of US healthcare costs) and built environment's 50% global carbon footprint create tailwinds amid chronic underinvestment.[2] Timing is ideal post-2022 fund launch, aligning with post-pandemic shifts toward personalized precision medicine and regenerative therapies, excluding lifestyle-only plays.[4] It influences the ecosystem by amplifying diverse founders in FemTech, medtech, and blue economy, fostering LP commitments and regional expansion (e.g., Asia/EMEA GPs), thus bridging funding gaps for innovations reducing population health burdens and climate risks.[1][3][4]
Maroon is poised to scale Maroon Venture Fund I LP through global GP hires in Asia and Middle East, intensifying deal flow in precision medicine and climate-health while hitting LP targets via its proven MOIC and risk framework.[3][4] Trends like AI-climate integration and longevity science will propel growth, potentially evolving its influence toward larger AUM and more exits in a market favoring impact-aligned returns. This positions Maroon as a differentiator in closing innovation gaps, amplifying its role from emerging manager to longevity sector leader.[2]
Key people at Maroon Invest Global.
